The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Challenges in liver cancer and possible treatment approaches
Open accessAbstract
Globally, liver cancer is the most frequent fatal malignancy; in the United States, it ranks fifth. Patients are often diagnosed with liver cancer in advanced stages, contributing to its poor prognosis. Of all liver cancer cases, >90% are hepatocellular carcinomas (HCCs) for which chemotherapy and immunotherapy are the best options for therapy. For liver cancer patients, new treatment options are necessary. Use of natural compounds and/or nanotechnology may provide patients with better outcomes with lower systemic toxicity and fewer side effects. Improved treatments can lead to better prognoses. Finally, in this review, we present some of the problems and current treatment options contributing to the poor outcomes for patients with liver cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials
Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013) · The AAPS Journal · doi:10.1208/s12248-012-9432-8 · Cited by 2,110
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30700-9 · Cited by 1,399
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010) · Hepatology · doi:10.1002/hep.23594 · Cited by 1,336
Diagnosis and Treatment of Hepatocellular Carcinoma
El-Serag, H. B., Marrero, J. A., Rudolph, L., & Reddy, K. R. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.090 · Cited by 1,137
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Black Pepper and its Pungent Principle-Piperine: A Review of Diverse Physiological Effects
Srinivasan, K. (2007) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390601062054 · Cited by 821
Gao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
New knowledge of the mechanisms of sorafenib resistance in liver cancer
Zhu, Y.-J., Zheng, B., Wang, H.-Y., & Chen, L. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.5 · Cited by 702
HUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
The Role of Angiogenesis in Hepatocellular Carcinoma
Morse, M. A., Sun, W., Kim, R., He, A. R., Abada, P. B., Mynderse, M., & Finn, R. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1254 · Cited by 533
Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4
Bhardwaj, R. K., Glaeser, H., Becquemont, L., Klotz, U., Gupta, S. K., & Fromm, M. F. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034728 · Cited by 444
Dietary Natural Products for Prevention and Treatment of Liver Cancer
Zhou, Y., Li, Y., Zhou, T., Zheng, J., Li, S., & Li, H.-B. (2016) · Nutrients · doi:10.3390/nu8030156 · Cited by 411
Koga, H., Sakisaka, S., Ohishi, M., Kawaguchi, T., Taniguchi, E., Sasatomi, K., Harada, M., Kusaba, T., Tanaka, M., Kimura, R., et al. (1999) · Hepatology · doi:10.1002/hep.510290355 · Cited by 396
Li, L., Tang, F., Liu, H., Liu, T., Hao, N., Chen, D., Teng, X., & He, J. (2010) · ACS Nano · doi:10.1021/nn100918a · Cited by 332
International Trends in Liver Cancer Incidence Rates
Center, M. M., & Jemal, A. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0643 · Cited by 309
Natural products in licorice for the therapy of liver diseases: Progress and future opportunities
Li, X., Sun, R., & Liu, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.04.025 · Cited by 256
The Inflammation and Liver Cancer
Bishayee, A. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-0348-0837-8_16 · Cited by 255
Different strategies to overcome multidrug resistance in cancer
Saraswathy, M., & Gong, S. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.06.004 · Cited by 248
Singh, S. K., Banerjee, S., Acosta, E. P., Lillard, J. W., & Singh, R. (2017) · Oncotarget · doi:10.18632/oncotarget.15303 · Cited by 236
Self-citationImmunotherapy of Hepatocellular Carcinoma: Facts and Hopes
Iñarrairaegui, M., Melero, I., & Sangro, B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0289 · Cited by 235
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Jelic, S., & Sotiropoulos, G. C. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq166 · Cited by 228
Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma
Kane, R. C., Farrell, A. T., Madabushi, R., Booth, B., Chattopadhyay, S., Sridhara, R., Justice, R., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0185 · Cited by 221
Drug delivery approaches for breast cancer
Singh, S., Singh, S., Lillard Jr, J. W., & Singh, R. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s140325 · Cited by 219
Self-citationChen, Y., Huang, Y., Reiberger, T., Duyverman, A. M., Huang, P., Samuel, R., Hiddingh, L., Roberge, S., Koppel, C., Lauwers, G. Y., et al. (2014) · Hepatology · doi:10.1002/hep.26790 · Cited by 211
Rationally designed nanovehicles to overcome cancer chemoresistance
Livney, Y. D., & Assaraf, Y. G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.006 · Cited by 205
Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in Japan
Kudo, M. (2015) · Liver Cancer · doi:10.1159/000367727 · Cited by 198
Huo, X., Han, S., Wu, G., Latchoumanin, O., Zhou, G., Hebbard, L., George, J., & Qiao, L. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0734-4 · Cited by 186
Targets for immunotherapy of liver cancer
Greten, T. F., & Sangro, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.007 · Cited by 168
Choi, G. H., Shim, J. H., Kim, M.-J., Ryu, M., Ryoo, B., Kang, Y., Shin, Y. M., Kim, K. M., Lim, Y., & Lee, H. C. (2013) · Radiology · doi:10.1148/radiol.13130150 · Cited by 148
the Liver Cancer Study Group of Japan, Nouso, K., Miyahara, K., Uchida, D., Kuwaki, K., Izumi, N., Omata, M., Ichida, T., Kudo, M., Ku, Y., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.542 · Cited by 147
Nanotechnology for therapy and imaging of liver diseases
Reddy, L. H., & Couvreur, P. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.039 · Cited by 145
Liu, W., Zhao, X., Chen, Q., Li, Y.-S., Tang, H., Liu, X., & Yang, X. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s73322 · Cited by 126
Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo
Reebye, V., Sætrom, P., Mintz, P. J., Huang, K., Swiderski, P. M., Peng, L., Liu, C., Liu, X., Lindkær-Jensen, S., Zacharoulis, D., et al. (2013) · Hepatology · doi:10.1002/hep.26669 · Cited by 126
Soerjomataram, I., Oomen, D. W. G. D., Lemmens, V. E. P. P., Oenema, A., Benetou, V., Trichopoulou, A., Coebergh, J. W. W., Barendregt, J. J., & de Vries, E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.026 · Cited by 123
Allium vegetables in cancer prevention: an overview.
Sengupta, A., Ghosh, S., & Bhattacharjee, S. (2004) · PubMed · Cited by 122
Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation
Zhang, G., Park, M. A., Mitchell, C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0469 · Cited by 113
Singh, S. K., Lillard, J. W., & Singh, R. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.017 · Cited by 113
Self-citationNg, K. T., Guo, D. Y., Cheng, Q., Geng, W., Ling, C. C., Li, C. X., Liu, X. B., Yuen, Y., Lo, C. M., Poon, R. T. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031655 · Cited by 102
The Biological Activities of Oleocanthal from a Molecular Perspective
Pang, K. L., & Chin, K. (2018) · Nutrients · doi:10.3390/nu10050570 · Cited by 99
Khazaei, S., Esa, N. M., Ramachandran, V., Hamid, R. A., Pandurangan, A. K., Etemad, A., & Ismail, P. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00005 · Cited by 97
Singh, R. (2017) · Frontiers in Bioscience-Elite · doi:10.2741/e798 · Cited by 97
Self-citationOleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation
Cusimano, A., Balasus, D., Azzolina, A., Augello, G., Emma, M. R., Sano, C. D., Gramignoli, R., Strom, S. C., McCubrey, J. A., Montalto, G., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4049 · Cited by 97
Expression of PD-1, PD-L1, and PD-L2 in the Liver in Autoimmune Liver Diseases
Mataki, N., Kikuchi, K., Kawai, T., Higashiyama, M., Okada, Y., Kurihara, C., Hokari, R., Kawaguchi, A., Nagao, S., Kondo, T., et al. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00948.x · Cited by 85
Gunasekaran, V., Elangovan, K., & Devaraj, S. N. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.03.029 · Cited by 85
Thymoquinone-based nanotechnology for cancer therapy: promises and challenges
Ballout, F., Habli, Z. S., Rahal, O. N., Fatfat, M., & Gali‐Muhtasib, H. U. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.043 · Cited by 82
Petrović, V., Nepal, A., Olaisen, C., Bachke, S., Hira, J., Søgaard, C. K., Røst, L. M., Misund, K., Andreassen, T., Melø, T. M., et al. (2018) · Nutrients · doi:10.3390/nu10040450 · Cited by 81
Pei, T., Meng, Q., Han, J., Sun, H., Li, L., Song, R., Sun, B., Pan, S., Liang, D., & Liu, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9782 · Cited by 80
Polini, B., Digiacomo, M., Carpi, S., Bertini, S., Gado, F., Saccomanni, G., Macchia, M., Nieri, P., Manera, C., & Fogli, S. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.06.021 · Cited by 77
Patial, V., Mahesh, S., Sharma, S., Pratap, K., Singh, D., & Padwad, Y. S. (2015) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2015.07.012 · Cited by 76
Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem-Like Cells
Pan, Q., Pan, K., Wang, Q.-J., Weng, D., Zhao, J.-J., Zheng, H.-X., Zhang, X.-F., Jiang, S.-S., Lv, L., Tang, Y., et al. (2014) · Stem Cells · doi:10.1002/stem.1850 · Cited by 72
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update
Kudo, M. (2016) · Liver Cancer · doi:10.1159/000449342 · Cited by 70
Jeong, J. B., Park, J. H., Lee, H. K., Ju, S. Y., Hong, S. C., Lee, J. R., Chung, G. Y., Lim, J. H., & Jeong, H. J. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.11.039 · Cited by 65
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)
Breitbach, C. J., Bell, J. C., Hwang, T.-H., Kirn, D. H., & Burke, J. (2015) · Oncolytic Virotherapy · doi:10.2147/ov.s59640 · Cited by 60
Luo, L.-J., Zhang, L.-P., Duan, C.-Y., Wang, B., He, N., Abulimiti, P., & Lin, Y. (2017) · Cancer Cell International · doi:10.1186/s12935-016-0380-8 · Cited by 48
Ho, C., Chen, H., Hu, R., & Lee, P. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919843463 · Cited by 29
Hong, H., An, J. C., Cruz, J. F. D., & Hwang, S.-G. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4916 · Cited by 25
Cruz, J. F. D., Kim, Y. S., Lumbera, W. M. L., & Hwang, S. G. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.15.6417 · Cited by 16
Revving Up Dendritic Cells while Braking PD-L1 to Jump-Start the Cancer-Immunity Cycle Motor
Coffelt, S. B., & de Visser, K. E. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.014 · Cited by 15
Cited by
Anjum, S., Hashim, M., Malik, S. A., Khan, M., Lorenzo, J. M., Abbasi, B. H., & Hano, C. (2021) · Cancers · doi:10.3390/cancers13184570 · Cited by 575
Interplay of oxidative stress, cellular communication and signaling pathways in cancer
Iqbal, M. J., Kabeer, A., Abbas, Z., Siddiqui, H. A., Calina, D., Sharifi-Rad, J., & Cho, W. C. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01398-5 · Cited by 418
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Sun, E. J., Wankell, M., Palamuthusingam, P., McFarlane, C., & Hebbard, L. (2021) · Biomedicines · doi:10.3390/biomedicines9111639 · Cited by 281
Liu, Y., Liu, Y., Sun, X., Wang, Y., Du, C., & Bai, J. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100903 · Cited by 19
Lu, S., Zhang, C., Wu, H., Wang, J., Wang, J., Zhao, L., Ren, T., & Li, G. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101801 · Cited by 8
Metadata
- Authors
- Anwanwan, D., Singh, S. K., Singh, S., Saikam, V., & Singh, R.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 1873
- Issue
- 1
- Pages
- 188314
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W2983258509
- Cited by
- 1,481
- References
- 74
- FWCI
- 58.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.